Covalent BTK mutations better understood as a ... - CLL Support
Covalent BTK mutations better understood as a result of studying those who progressed on acalabrutinib or ibrutinib in the ELEVATE R/R trial
You need to be a member of this community to see this post.
Read more about...
5 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
BRUIN Study: phase 1/2 study of Pirtobrutinib (formerly Loxo 305) in relapsed or refractory B-cell malignancies
Patients discontinue BTKi's due to resistance and intolerance. We evaluated the safety and efficacy...
YABTKi or Yet Another BTK inhibitor - an A to Z list of Bruton's Tyrosine Kinase Inhibitors and Degraders following ibrutinib's success
I'll admit that YABTKi is not a recognised CLL related acronym, (acronym lists are here...
BTK Degrader Shows Potential for Treating Refractory CLL and SLL
A novel Bruton's tyrosine kinase (BTK) degrader, NX-2127, has shown potential for treating patients...
BTK inhibitor challenges by Dr. Nicole Lamanna
Nicole Lamanna, MD, continues her discussion on BTK inhibitor challenges....
Attention Those Taking Ibrutinib & BTK Inhibitors:Second Cancer Incidence in CLL Patients Receiving BTK Inhibitors
The publication examines the relationship between the use of ibrutinib and acalabrutinib with the...
Related Posts
BTK inhibitors for the treatment of CLL - the current state of play of 'brutinibs'- Resistance-Associated Mutations in CLL Patients Treated With Novel Agents
- Zanubrutinib looks promising on all fronts in first interim analysis of ALPINE Trial - Ibrutinib v Zanubrutinib in R/R CLL - report from EHA
- First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia.
- NICE Recommends Acalabrutinib for treating CLL for certain groups
